All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Comparative Study on the Use of Long-Acting Injectable Antipsychotics in Three Different Psychiatric Treatment Facilities in Saskatchewan, Canada

DOI: 10.4236/oalib.1106530, PP. 1-17

Subject Areas: Nursing

Keywords: Prescription, Long Acting Injectable, Polypharmacy, Dosage Intervals, Antipsychotics, Schizophrenia, Bipolar Disorder

Full-Text   Cite this paper   Add to My Lib

Abstract

This study examined the prevalence of Long Acting Injectable (LAI) antipsychotics prescription and explored the nature and scope of such prescriptions in the context of polypharmacy in three major psychiatric treatment facilities in Saskatchewan, Canada. A cross-sectional study approach was used to collect data on LAI antipsychotics prescription details and de-identified demographics on all patients on admission on a specified date at the three study sites. Despite the availability of second generation LAI antipsychotics, first generation LAI antipsychotics accounted for 83.3% of the prescriptions (N = 96). Risperdal Consta was the only second generation LAI antipsychotic medication prescribed out of the six LAI antipsychotics in use. The most commonly prescribed LAI antipsychotic was zuclopenthixol decanoate (44.1%, N = 53). Most of the LAI antipsychotics were prescribed within the recommended dosages. Biweekly administration was the most common interval for the prescription of LAI antipsychotics (75%, N = 90). Polypharmacy was present amongst all patients including those on LAI antipsychotics. Co-prescription of antiparkinsonian medication was associated with the prescription of LAI antipsychotics. Patients with the diagnosis of Schizophrenia had more prescriptions for Zuclopenthixol decanoate (44.4%) and Risperidone Consta (24.4%) than those with the diagnoses of bipolar disorder (23.3% and 14.7%, respectively). A longitudinal approach to examining the LAI antipsychotic prescription practice would help to determine if concomitant prescription of LAI antipsychotics is associated with decrease in oral antipsychotic load.

Cite this paper

Adelugba, O. O. , Haq, I. U. , Mela, M. , Gu, D. , Obikoya, O. and Garratt, L. (2020). Comparative Study on the Use of Long-Acting Injectable Antipsychotics in Three Different Psychiatric Treatment Facilities in Saskatchewan, Canada. Open Access Library Journal, 7, e6530. doi: http://dx.doi.org/10.4236/oalib.1106530.

References

[1]  Song, W.S., Cha, J.H., Yoon, S.H., Cho, Y.S., Park, K.Y. and Kim, M.H. (2017) The Atypical Antipsychotic Olanzapine Disturbs Depotentiation by Modulating mAChRs and Impairs Reversal Learning. Neuropharmacology, 114, 1-11. https://doi.org/10.1016/j.neuropharm.2016.11.012
[2]  Bond, D., Pratoomsri, W. and Yatham, L. (2007) Depot Antipsychotic Medications in Bipolar Disorder: A Review of the Literature. Acta Psychiatrica Scandinavica, 116, 3-16. https://doi.org/10.1111/j.1600-0447.2007.01054.x
[3]  De Risio, A. and P Lang, A. (2014) History and Therapeutic Rationale of Long Acting Antipsychotics. Current Clinical Pharmacology, 9, 39-52. https://doi.org/10.2174/15748847113089990057
[4]  Malempati, R.N., Bond, D.J. and Yatham, L.N. (2008) Depot Risperidone in the Outpatient Management of Bipolar Disorder: A 2-Year Study of 10 Patients. International Clinical Psychopharmacology, 23, 88-94. https://doi.org/10.1097/YIC.0b013e3282f2b4c5
[5]  Chang, W.C., Wong, C.S.M., Chen, E.Y.H., Lam, L.C.W., Chan, W.C., Ng, R.M.K., Bebbington, P., et al. (2017) Lifetime Prevalence and Correlates of Schizophrenia-Spectrum, Affective, and Other Non-Affective Psychotic Disorders in the Chinese Adult Population. Schizophrenia Bulletin, 43, 1280-1290. https://doi.org/10.1093/schbul/sbx056
[6]  N?rgaard, A., Jensen-Dahm, C., Gasse, C., Hansen, E.S. and Waldemar, G. (2017) Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors. Journal of Alzheimer’s Disease, 56, 707-716. https://doi.org/10.3233/JAD-160828
[7]  Weber, S.R., Wehr, A.M. and Duchemin, A.M. (2016) Prevalence of Antipsychotic Prescriptions among Patients with Anxiety Disorders Treated in Inpatient and Outpatient Psychiatric Settings. Journal of Affective Disorders, 191, 292-299. https://doi.org/10.1016/j.jad.2015.11.031
[8]  Bossie, C.A., Alphs, L.D. and Correll, C.U. (2015) Long-Acting Injectable versus Daily Oral Antipsychotic Treatment Trials in Schizophrenia: Pragmatic versus Explanatory Study Designs. International Clinical Psychopharmacology, 30, 272-281. https://doi.org/10.1097/YIC.0000000000000082
[9]  Suzuki, T. (2016) A Further Consideration on Long-Acting Injectable versus Oral Antipsychotics in the Treatment of Schizophrenia: A Narrative Review and Critical Appraisal. Expert Opinion on Drug Delivery, 13, 253-264. https://doi.org/10.1517/17425247.2016.1115479
[10]  Doey, T., Handelman, K., Seabrook, J.A. and Steele, M. (2007) Survey of Atypical Antipsychotic Prescribing by Canadian Child Psychiatrists and Developmental Pediatricians for Patients aged under 18 Years. The Canadian Journal of Psychiatry, 52, 363-368. https://doi.org/10.1177/070674370705200605
[11]  Larose, D.S., Landry, C. and Collerette, C. (1999) Overuse of Psychotropic Drugs in Seniors. Canadian Nurse, 95, 45-50.
[12]  Martin, K., Arora, V., Fischler, I. and Tremblay, R. (2017) Descriptive Analysis of Pro Re Nata Medication Use at a Canadian Psychiatric Hospital. International Journal of Mental Health Nursing, 26, 402-408. https://doi.org/10.1111/inm.12265
[13]  Warnock, C.A., Ferguson, I.D. and Lam, J. (2014) Psychotropic Drug Prescribing Survey in a Canadian Rehabilitation and Complex Care Facility. Consultant Pharmacist, 29, 387-399. https://doi.org/10.4140/TCP.n.2014.387
[14]  Heald, A., Livingston, M., Yung, A. and De Hert, M.A. (2017) Prescribing in Schizophrenia and Psychosis: Increasing Polypharmacy over Time. Human Psychopharmacology Clinical and Experimental, 32, e2579. https://doi.org/10.1002/hup.2579
[15]  Herr, M., Grondin, H., Sanchez, S., Armaingaud, D., Blochet, C., Vial, A., Ankri, J., et al. (2017) Polypharmacy and Potentially Inappropriate Medications: A Cross-Sectional Analysis among 451 Nursing Homes in France. European Journal of Clinical Pharmacology, 73, 601-608. https://doi.org/10.1007/s00228-016-2193-z
[16]  Hamann, J., Kissling, W. and Heres, S. (2014) Checking the Plausibility of Psychiatrists’ Arguments for Not Prescribing Depot Medication. European Neuropsychopharmacology, 24, 1506-1510. https://doi.org/10.1016/j.euroneuro.2014.06.015
[17]  Wu, Z., Baillargeon, J., Grady, J., Black, S. and Dunn, K. (2001) HIV Seroprevalence among Newly Incarcerated Inmates in the Texas Correctional System. Annals of Epidemiology, 11, 342-346. https://doi.org/10.1016/S1047-2797(01)00210-1
[18]  Fazel, S. and Danesh, J. (2002) Serious Mental Disorder in 23000 Prisoners: A Systematic Review of 62 Surveys. The Lancet, 359, 545-550. https://doi.org/10.1016/S0140-6736(02)07740-1
[19]  Baweja, R., Sedky, K. and Lippmann, S. (2012) Long-Acting Antipsychotic Medications. Current Cancer Drug Targets, 13, 555-560. https://doi.org/10.2174/138945012799499785
[20]  Arango, C., Bombin, I., Gonzalez-Salvador, T., Garcia-Cabeza, I. and Bobes, J. (2006) Randomised Clinical Trial Comparing Oral versus Depot Formulations of Zuclopenthixol in Patients with Schizophrenia and Previous Violence. European Psychiatry, 21, 34-40. https://doi.org/10.1016/j.eurpsy.2005.07.006
[21]  Buckley, P.F., Noffsinger, S.G., Smith, D.A., Hrouda, D.R. and Knoll, J.L. (2003) Treatment of the Psychotic Patient Who Is Violent. Psychiatric Clinics of North America, 26, 231-272. https://doi.org/10.1016/S0193-953X(02)00029-1
[22]  Priebe, S., Burton, A., Ashby, D.R.A., Burns, T., David, A., McCabe, R., et al. (2009) Financial Incentives to Improve Adherence to Anti-Psychotic Maintenance Medication in Non-Adherent Patients—A Cluster Randomised Controlled Trial (FIAT). BMC Psychiatry, 9, 61. https://doi.org/10.1186/1471-244X-9-61
[23]  Arnold, R., Giebe, W., Winnefeld, K. and Klein, A. (2002) An Initially Unexplained Death during Prison Sentence. Diagnostic Verification by Atomic Absorption Spectrometry. Archiv fur Kriminologie, 209, 14-19.
[24]  Barnes, T.R., Shingleton-Smith, A. and Paton, C. (2009) Antipsychotic Long-Acting Injections: Prescribing Practice in the UK. The British Journal of Psychiatry, 195, s37-s42. https://doi.org/10.1192/bjp.195.52.s37
[25]  Bobo, W.V. and Shelton, R.C. (2010) Risperidone Long-Acting Injectable (Risperdal Consta?) for Maintenance Treatment in Patients with Bipolar Disorder. Expert Review of Neurotherapeutics, 10, 1637-1658. https://doi.org/10.1586/ern.10.143
[26]  Lasser, R.A., Bossie, C.A., Gharabawi, G.M. and Turner, M. (2004) Patients with Schizophrenia Previously Stabilized on Conventional Depot Antipsychotics Experience Significant Clinical Improvements Following Treatment with Long-Acting Risperidone. European Psychiatry, 19, 219-225. https://doi.org/10.1016/j.eurpsy.2003.11.007
[27]  Cramer, J.A. and Rosenheck, R. (1998) Compliance with Medication Regimens for Mental and Physical Disorders. Psychiatric Services, 49, 196-201. https://doi.org/10.1176/ps.49.2.196
[28]  Graffino, M., Montemagni, C., Mingrone, C. and Rocca, P. (2014) Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia: A Review of Literature. Rivista di Psichiatria, 49, 115-123.
[29]  Young, J.L., Spitz, R.T., Hillbrand, M. and Daneri, G. (1999) Medication Adherence Failure in Schizophrenia: A Forensic Review of Rates, Reasons, Treatments, and Prospects. Journal of the American Academy of Psychiatry and the Law Online, 27, 426-444.
[30]  Achilla, E. and McCrone, P. (2013) The Cost Effectiveness of Long Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia: A Systematic Review of Economic Evaluations. Applied Health Economics and Health Policy, 11, 95-106. https://doi.org/10.1007/s40258-013-0016-2
[31]  RPC (2009) Overview of Regional Psychiatric Centre.
[32]  Thomson, L.D. (2000) Management of Schizophrenia in Conditions of High Security. Advances in Psychiatric Treatment, 6, 252-260. https://doi.org/10.1192/apt.6.4.252
[33]  SPSS, I. (2011) SPSS Statistics for Windows. IBM Corp., Armonk.
[34]  CPS (2018) Compendium of Pharmacist and Specialist. Canadian Pharmacists Association, Ottawa.
[35]  Rossi, G., Frediani, S., Rossi, R. and Rossi, A. (2012) Long-Acting Antipsychotic Drugs for the Treatment of Schizophrenia: Use in Daily Practice from Naturalistic Observations. BMC Psychiatry, 12, 122. https://doi.org/10.1186/1471-244X-12-122
[36]  Albayrak, Y., Unsal, C. and Beyazyuz, M. (2013) Relationships between Use of Long Acting Antipsychotics and Sociodemographic and Clinical Characteristics of Patients with Schizophrenia. Bulletin of Clinical Psychopharmacology, 23, 171-179. https://doi.org/10.5455/bcp.20130408021412
[37]  Soleman, M., Lam, N. and Woo, B. (2017) Ethnic and Age Disparities in Patients Taking Long-Acting Injectable Atypical Antipsychotics. Cureus, 9, e1772. https://doi.org/10.7759/cureus.1772
[38]  Sim, K., Su, A., Ungvari, G.S., Fujii, S., Yang, S.Y., Chong, M.Y., Tan, C.H., et al. (2004) Depot Antipsychotic Use in Schizophrenia: An East Asian Perspective. Human Psychopharmacology, 19, 103-109. https://doi.org/10.1002/hup.571
[39]  Acquaviva, E., Gasquet, I. and Falissard, B. (2005) Psychotropic Combination in Schizophrenia. European Journal of Clinical Pharmacology, 61, 855-861. https://doi.org/10.1007/s00228-005-0034-6
[40]  Tan, C.H., Shinfuku, N., Sim, K., Tan, C.-H., Shinfuku, N. and Sim, K. (2008) Psychotropic Prescription Practices in East Asia: Looking Back and Peering Ahead. Current Opinion in Psychiatry, 21, 645-650. https://doi.org/10.1097/YCO.0b013e32830e6dc4
[41]  Manchanda, R., Chue, P., Malla, A., Tibbo, P., Roy, M.-A., Williams, R., Banks, N., et al. (2013) Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use. The Canadian Journal of Psychiatry, 58, 5S-13S. https://doi.org/10.1177/088740341305805s02
[42]  Liu, C.-C., Shan, J.-C., Chiang, C.-L., Hsieh, M.H., Liu, C.-M., Chien, Y.-L., Hwang, T.-J., et al. (2015) Initiating Long-Acting Injectable Antipsychotics during Acute Admission for Patients with Schizophrenia—A 3-Year Follow-Up. Journal of the Formosan Medical Association, 114, 539-545. https://doi.org/10.1016/j.jfma.2013.01.004
[43]  Samalin, L., de Chazeron, I., Vieta, E., Bellivier, F. and Llorca, P.M. (2016) Residual Symptoms and Specific Functional Impairments in Euthymic Patients with Bipolar Disorder. Bipolar Disorders, 18, 164-173. https://doi.org/10.1111/bdi.12376
[44]  Lammers, L., Zehm, B. and Williams, R. (2013) Risperidone Long-Acting Injection in Schizophrenia Spectrum Illnesses Compared to First Generation Depot Antipsychotics in an Outpatient Setting in Canada. BMC Psychiatry, 13, 155. https://doi.org/10.1186/1471-244X-13-155
[45]  Llorca, P.M., Bobes, J., Fleischhacker, W.W., Heres, S., Moore, N., Bent-Ennakhil, N., Patel, M.X., et al. (2018) Baseline Results from the European Non-Interventional Antipsychotic Long Acting Injection in Schizophrenia (ALTO) Study. European Psychiatry, 52, 85-94. https://doi.org/10.1016/j.eurpsy.2018.04.004
[46]  Armstrong, K.S. and Temmingh, H. (2017) Prevalence of and Factors Associated with Antipsychotic Polypharmacy in Patients with Serious Mental Illness: Findings from a Cross-Sectional Study in an Upper-Middle-Income Country. Revista Brasileira de Psiquiatria, 39, 293-301. https://doi.org/10.1590/1516-4446-2016-2015
[47]  Doshi, J.A., Pettit, A.R., Stoddard, J.J., Zummo, J. and Marcus, S.C. (2015) Concurrent Oral Antipsychotic Drug Use among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge. Journal of Clinical Psychopharmacology, 35, 442-446. https://doi.org/10.1097/JCP.0000000000000353
[48]  Rehse, M., Bartolovic, M., Baum, K., Richter, D., Weisbrod, M. and Roesch-Ely, D. (2016) Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia. Schizophrenia Research and Treatment, 2016, Article ID: 8213165. https://doi.org/10.1155/2016/8213165
[49]  Yang, S.Y., Chen, L.Y., Najoan, E., Kallivayalil, R.A., Viboonma, K., Jamaluddin, R., Lin, S.K., et al. (2018) Polypharmacy and Psychotropic Drug Loading in Patients with Schizophrenia in Asian Countries: Fourth Survey of Research on Asian Prescription Patterns on Antipsychotics. Psychiatry and Clinical Neurosciences, 72, 572-579. https://doi.org/10.1111/pcn.12676
[50]  Yoshio, T. (2012) The Trend for Megadose Polypharmacy in Antipsychotic Pharmacotherapy: A Prescription Survey Conducted by the Psychiatric Clinical Pharmacy Research Group. Seishin Shinkeigaku Zasshi, 114, 690-695.
[51]  Yamanouchi, Y., Sukegawa, T., Inagaki, A., Inada, T., Yoshio, T., Yoshimura, R. and Iwata, N. (2014) Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method. International Journal of Neuropsychopharmacology, 18, pyu016. https://doi.org/10.1093/ijnp/pyu016
[52]  Spanarello, S. and La Ferla, T. (2014) The Pharmacokinetics of Long-Acting Antipsychotic Medications. Current Clinical Pharmacology, 9, 310-317. https://doi.org/10.2174/15748847113089990051

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal